Scientists at the New York Genome Center (NYGC) and New York University (NYU) say they have begun to facilitate broad access to single-cell sequencing by developing a 3D-printed, portable, and low-cost microfluidic controller. To demonstrate the utility of the instrument in clinical environments, the researchers deployed the device to study synovial tissue from patients with rheumatoid arthritis (RA) at the Hospital for Special Surgery (HSS). The precise cause of RA is undetermined and muddled by the diversity of cells found in the swollen joints of patients.
In the study (“Single-Cell RNA-Seq of Rheumatoid Arthritis Synovial Tissue Using Low-Cost Microfluidic Instrumentation”), published in Nature Communications, the researchers describe the 3D-printed custom device, which, along with its electronic and pneumatic components, can be obtained and assembled for a total cost of about $600. The device occupies a small footprint as well, not much larger than a tissue box.
“Droplet-based single-cell RNA-seq has emerged as a powerful technique for massively parallel cellular profiling. While this approach offers the exciting promise to deconvolute cellular heterogeneity in diseased tissues, the lack of cost-effective and user-friendly instrumentation has hindered widespread adoption of droplet microfluidic techniques,” write the investigators.
“To address this, we developed a 3D-printed, low-cost droplet microfluidic control instrument and deploy it in a clinical environment to perform single-cell transcriptome profiling of disaggregated synovial tissue from five rheumatoid arthritis patients. We sequence 20,387 single cells revealing 13 transcriptomically distinct clusters. These encompass an unsupervised draft atlas of the autoimmune infiltrate that contribute to disease biology. Additionally, we identify previously uncharacterized fibroblast subpopulations and discern their spatial location within the synovium. We envision that this instrument will have broad utility in both research and clinical settings, enabling low-cost and routine application of microfluidic techniques.”
“Most commercial microfluidic instruments are very costly; as a result, not every lab has access to exciting technology for single-cell analysis,” said William Stephenson Ph.D., senior research engineer in the NYGC's Technology Innovation Lab, who led the development of the instrument and is a lead author on the study. “We designed the instrument to perform droplet microfluidics and in particular Drop-seq, a massively parallel technology for single cell RNA-sequencing.”
The portability of the controller permitted patient samples to be processed on site and immediately after surgery, minimizing handling and transport to optimize sample quality. The researchers collected samples from five RA patients totaling 20,387 cells and looked at the individual gene expression patterns for each cell.
“This dataset gave us the opportunity to identify individual subpopulations of cells that could drive the progression of RA, even if they have not been previously characterized,” said Rahul Satija Ph.D., a Core Faculty Member at NYGC, assistant professor of biology at NYU, and senior author on the study.
By analyzing the complete dataset and searching for clusters of similar cells, the researchers identified 13 groups, representing both infiltrating immune and inflamed stromal populations. Of particular interest were distinct groups of fibroblasts with strikingly different gene expression patterns.
“Roughly an hour after surgical excision, individual cells from patient tissues were labeled for single-cell sequencing. From this work, we have classified unrecognized fibroblast subtypes that may prove to be important drug targets for our RA patients,” said Laura Donlin, Ph.D., co-director of the HSS Precision Medicine Lab and assistant professor at Weill Cornell Medicine, and a lead author on the study.
The researchers were able to validate the presence of these multiple groups using flow cytometry and discovered that they exhibited distinct localization patterns with the joint tissue as well.
The dataset is a step toward creating a comprehensive “cell atlas” for synovial tissue from RA patients, according to the scientists. Moving forward, the researchers are compiling data from additional RA patients, and aim to obtain patient samples from other arthritic conditions, such as psoriatic arthritis and osteoarthritis. In addition, they plan to use CITE-seq, a technique also developed in the Technology Innovation Lab at the NYGC, to more precisely classify cell types by measuring the presence of surface proteins in addition to the transcriptome.
They also envision that technology will be useful for profiling samples that are difficult to study in a standard lab, such as highly infectious samples in biocontainment facilities or samples being collected in field research settings. To facilitate its widespread use in the scientific and medical community, the instrument has been fully “open-sourced.” Instructions and assembly manuals for the instrument can be found online at the popular microfluidics repository Metafluidics.
“We hope that this instrument lowers the hurdles associated with performing single-cell transcriptome profiling experiments in basic research and clinical settings,” Dr. Stephenson said.
